{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "f7d00e01",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd \n",
    "import numpy as np\n",
    "import os, sys\n",
    "from tqdm import tqdm\n",
    "import warnings\n",
    "warnings.filterwarnings('ignore')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "baff4756",
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "from bs4 import BeautifulSoup"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "9eb05346",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<!DOCTYPE html>\n",
       "\n",
       "<!-- This is the same as the normal base, except that it does not include a nav bar.\n",
       "For react pages, the nav bar is a react component, so we don't want a duplicate here -->\n",
       "<html class=\"no-js\" lang=\"en\">\n",
       "<head>\n",
       "<!-- Google Tag Manager -->\n",
       "<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':\n",
       "    new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],\n",
       "    j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=\n",
       "    'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);\n",
       "    })(window,document,'script','dataLayer','GTM-NQTMJMG');</script>\n",
       "<!-- End Google Tag Manager -->\n",
       "<meta charset=\"utf-8\"/>\n",
       "<meta content=\"IE=edge\" http-equiv=\"X-UA-Compatible\"/>\n",
       "<meta content=\"width=device-width, initial-scale=1.0\" name=\"viewport\"/>\n",
       "<!-- The above 3 meta tags *must* come first in the head; any other head content must come *after* these tags -->\n",
       "<title>Drug Search - My Cancer Genome</title>\n",
       "<!-- HTML5 shim and Respond.js for IE8 support of HTML5 elements and media queries -->\n",
       "<!-- WARNING: Respond.js doesn't work if you view the page via file:// -->\n",
       "<!--[if lt IE 9]>\n",
       "      <script src=\"https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js\"></script>\n",
       "      <script src=\"https://oss.maxcdn.com/respond/1.4.2/respond.min.js\"></script>\n",
       "    <![endif]-->\n",
       "<!-- Compressed CSS -->\n",
       "<link crossorigin=\"anonymous\" href=\"https://cdnjs.cloudflare.com/ajax/libs/foundation/6.3.1/css/foundation.min.css\" integrity=\"sha256-itWEYdFWzZPBG78bJOOiQIn06QCgN/F0wMDcC4nOhxY=\" rel=\"stylesheet\"/>\n",
       "<link href=\"/static/css/style.bea0e8e2f2dd.css\" rel=\"stylesheet\" type=\"text/css\"/>\n",
       "<script async=\"\" src=\"https://www.googletagmanager.com/gtag/js?id=UA-108343297-1\"></script>\n",
       "<script>\n",
       "      window.dataLayer = window.dataLayer || [];\n",
       "      function gtag(){dataLayer.push(arguments);}\n",
       "      gtag('js', new Date());\n",
       "      gtag('config', 'UA-108343297-1');\n",
       "    </script>\n",
       "</head>\n",
       "<body>\n",
       "<!-- Google Tag Manager (noscript) -->\n",
       "<noscript><iframe height=\"0\" src=\"https://www.googletagmanager.com/ns.html?id=GTM-NQTMJMG\" style=\"display:none;visibility:hidden\" width=\"0\"></iframe></noscript>\n",
       "<!-- End Google Tag Manager (noscript) -->\n",
       "<div class=\"main-content\">\n",
       "<div id=\"drug-listing\">\n",
       "<div class=\"row\">\n",
       "<div class=\"large-12 columns\">\n",
       "<h4>Drugs</h4>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "<div class=\"sticky-footer\">\n",
       "<div class=\"footer-bar\">\n",
       "</div>\n",
       "<!-- Footer -->\n",
       "<div class=\"row footer expanded dark-grey-background\">\n",
       "<div class=\"columns small-12 medium-6 medium-offset-1\">\n",
       "<div class=\"row\">\n",
       "<div class=\"columns small-12 medium-4\">\n",
       "<h6><strong>About</strong></h6>\n",
       "<p class=\"small-p\"><a href=\"/\">Home</a></p>\n",
       "<p class=\"small-p\"><a href=\"/content/page/what-is-my-cancer-genome\">What Is My Cancer Genome?</a></p>\n",
       "<p class=\"small-p\"><a href=\"/content/page/my-cancer-genome-data-sources\">My Cancer Genome Data Sources</a></p>\n",
       "<p class=\"small-p\"><a href=\"/content/page/legal-policies-licensing\">Legal Policies &amp; Licensing</a></p>\n",
       "<p class=\"small-p\"><a href=\"/content/page/letter-from-the-editors\">Letter from the Editors</a></p>\n",
       "<p class=\"small-p\"><a href=\"/content/page/acknowledgments\">Acknowledgments</a></p>\n",
       "<p class=\"small-p\"><a href=\"https://genomoncology.com/\" target=\"_blank\">About GenomOncology</a></p>\n",
       "<p class=\"small-p\"><a href=\"/content/page/contributors\">Contributors</a></p>\n",
       "<p class=\"small-p\"><a href=\"/content/page/how-to-give-to-my-cancer-genome\">How to Give to My Cancer Genome</a></p>\n",
       "</div>\n",
       "<div class=\"columns small-12 medium-4\">\n",
       "<h6><strong>Molecular Medicine</strong></h6>\n",
       "<p class=\"small-p\"><a href=\"/content/page/molecular-testing\">Types of Molecular Tumor Testing</a></p>\n",
       "<p class=\"small-p\"><a href=\"/content/page/circulating-dna\">Circulating DNA</a></p>\n",
       "<p class=\"small-p\"><a href=\"/content/page/detecting-gene-alterations-in-cancers\">Detecting Gene Alterations in Cancers</a></p>\n",
       "<p class=\"small-p\"><a href=\"/content/glossary\">Glossary</a></p>\n",
       "<p class=\"small-p\"><a href=\"/content/page/overview-of-targeted-therapies-for-cancer\">Targeted Therapies</a></p>\n",
       "<p class=\"small-p\"><a href=\"/content/page/molecular-tumor-board\">Molecular Tumor Board</a></p>\n",
       "</div>\n",
       "<div class=\"columns small-12 medium-4\">\n",
       "<h6><strong>Content Types</strong></h6>\n",
       "<p class=\"small-p\"><a href=\"/content/clinical_trials/\">Clinical Trials</a></p>\n",
       "<p class=\"small-p\"><a href=\"/content/disease\">Diseases</a></p>\n",
       "<p class=\"small-p\"><a href=\"/content/biomarkers/\">Biomarkers</a></p>\n",
       "<p class=\"small-p\"><a href=\"/content/drugs/\">Drugs</a></p>\n",
       "<p class=\"small-p\"><a href=\"/content/pathways/\">Pathways</a></p>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "<div class=\"columns small-12 medium-4 end logo-footer\">\n",
       "<img src=\"/static/img/PoweredHiRes.4ffcb7daa2b2.png\"/>\n",
       "<footer class=\"small-p\">My Cancer Genome is managed by the<br/><a href=\"http://www.vicc.org/\" target=\"_blank\"><u>Vanderbilt-Ingram Cancer Center</u></a></footer>\n",
       "<footer class=\"small-p\">Copyright © 2010 - 2017 MY CANCER GENOME</footer>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "<script src=\"/static/dist/jquery.js\"></script>\n",
       "<script src=\"/static/dist/what-input.js\"></script>\n",
       "<script src=\"/static/dist/foundation.min.js\"></script>\n",
       "<script src=\"/static/dist/app.js\"></script>\n",
       "</body>\n",
       "<link href=\"/static/css/Cards.bc5554feb5ad.css\" rel=\"stylesheet\" type=\"text/css\"/>\n",
       "<link href=\"/static/css/Filters.fa9264e0857d.css\" rel=\"stylesheet\" type=\"text/css\"/>\n",
       "<link href=\"/static/css/for-smol-screens.7c43220055e5.css\" rel=\"stylesheet\" type=\"text/css\"/>\n",
       "<script type=\"text/javascript\">\n",
       "      var __MCG_URL__ = 'https://www.mycancergenome.org/mcg/';\n",
       "      var __MCG_API_TOKEN__ = '989c38a36eec154f01167274dbce2334ccf8ef11';\n",
       "    </script>\n",
       "<script src=\"/static/dist/bundled/drug_listing.bundle.91c4b1747321.js\"></script>\n",
       "</html>"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "BeautifulSoup(requests.get('https://www.mycancergenome.org/content/drugs/#sources=FDA').text, 'html.parser')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "78431c4d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "8"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "soup = BeautifulSoup(requests.get('https://www.mycancergenome.org/content/drugs/pembrolizumab/').text, 'html.parser')\n",
    "entries = soup.find_all('div', class_='about-drug-therapy-row')\n",
    "len(entries)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "9df4fdba",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "                    Non-Small Cell Lung Carcinoma\n",
      "                    +\n",
      " \n",
      "\n",
      "Disease is predicted to be sensitive to pembrolizumab:\n",
      "-\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Biomarker Criteria:\n",
      "Sample must match all of the following:PD-L1 Low Expression\n",
      "\n",
      "\n",
      "\n",
      "Clinical Setting(s):  Metastatic (FDA, NCCN, ASCO)\n",
      "\n",
      "\n",
      "Note:  For low expression of PD-L1 (Tumor Proportion Score >= 1% and <50%, clone 22C3) in the absence of EGFR & ALK (FDA/NCCN) and ROS1, RET, BRAF V600E, and MET Exon 14 Skipping (NCCN) mutations: recommended as a single agent for first-line therapy (for patients with contraindications to combination chemotherapy, per NCCN), or as subsequent line with disease progression during or following appropriate systemic chemotherapy.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Biomarker Criteria:\n",
      "Sample must match all of the following:PD-L1 Low Expression\n",
      "\n",
      "Clinical Setting(s):  Metastatic (FDA, NCCN, ASCO)\n",
      "\n",
      "\n",
      "Note:  For low expression of PD-L1 (Tumor Proportion Score >= 1% and <50%, clone 22C3) in the absence of EGFR & ALK (FDA/NCCN) and ROS1, RET, BRAF V600E, and MET Exon 14 Skipping (NCCN) mutations: recommended as a single agent for first-line therapy (for patients with contraindications to combination chemotherapy, per NCCN), or as subsequent line with disease progression during or following appropriate systemic chemotherapy.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Biomarker Criteria:\n",
      "Sample must match all of the following:PD-L1 High Expression\n",
      "\n",
      "\n",
      "\n",
      "Clinical Setting(s):  Metastatic (FDA, NCCN, ASCO)\n",
      "\n",
      "\n",
      "Note:  For high expression of PD-L1 (Tumor Proportion Score >= 50%, clone 22C3) in the absence of EGFR & ALK (FDA/NCCN) and ROS1, RET, BRAF V600E, and MET Exon 14 Skipping (NCCN) mutations: recommended as a single agent for first-line therapy, or as subsequent line with disease progression during or following appropriate systemic chemotherapy.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Biomarker Criteria:\n",
      "Sample must match all of the following:PD-L1 High Expression\n",
      "\n",
      "Clinical Setting(s):  Metastatic (FDA, NCCN, ASCO)\n",
      "\n",
      "\n",
      "Note:  For high expression of PD-L1 (Tumor Proportion Score >= 50%, clone 22C3) in the absence of EGFR & ALK (FDA/NCCN) and ROS1, RET, BRAF V600E, and MET Exon 14 Skipping (NCCN) mutations: recommended as a single agent for first-line therapy, or as subsequent line with disease progression during or following appropriate systemic chemotherapy.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Biomarker Criteria:\n",
      "Sample must match all of the following:Sample must match one or more of the following:PD-L1 High Expression, PD-L1 Low ExpressionSample must match one or more of the following:ALK Fusion, EGFR A763_Y764insFQEA, EGFR Exon 19 Deletion, EGFR Exon 19 Insertion, EGFR G719A, EGFR G719C, EGFR G719S, EGFR L858R, EGFR L861Q, EGFR S768I, EGFR T790M\n",
      "\n",
      "\n",
      "\n",
      "Clinical Setting(s):  Metastatic (FDA)\n",
      "\n",
      "\n",
      "Note:  For PD-L1 expressing tumors (Tumor Proportion Score >=1%, clone 22C3) with an EGFR or ALK alteration: FDA-approved as subsequent line of therapy following targeted therapy. However, per NCCN, data in the second-line setting suggest that subsequent pembrolizumab monotherapy is less effective in tumors with an EGFR mutation or ALK rearrangement.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Biomarker Criteria:\n",
      "Sample must match all of the following:Sample must match one or more of the following:PD-L1 High Expression, PD-L1 Low ExpressionSample must match one or more of the following:ALK Fusion, EGFR A763_Y764insFQEA, EGFR Exon 19 Deletion, EGFR Exon 19 Insertion, EGFR G719A, EGFR G719C, EGFR G719S, EGFR L858R, EGFR L861Q, EGFR S768I, EGFR T790M\n",
      "\n",
      "Clinical Setting(s):  Metastatic (FDA)\n",
      "\n",
      "\n",
      "Note:  For PD-L1 expressing tumors (Tumor Proportion Score >=1%, clone 22C3) with an EGFR or ALK alteration: FDA-approved as subsequent line of therapy following targeted therapy. However, per NCCN, data in the second-line setting suggest that subsequent pembrolizumab monotherapy is less effective in tumors with an EGFR mutation or ALK rearrangement.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Biomarker Criteria:\n",
      "Sample must match all of the following:Sample must match one or more of the following:PD-L1 High Expression, PD-L1 Low ExpressionSample must match one or more of the following:BRAF V600E, RET Fusion, ROS1 Fusion, MET Exon 14 Skipping\n",
      "\n",
      "\n",
      "\n",
      "Clinical Setting(s):  Metastatic (FDA, NCCN)\n",
      "\n",
      "\n",
      "Note:  For PD-L1 expressing tumors (Tumor Proportion Score >=1%, clone 22C3) with a ROS1, RET, BRAF V600E, or MET Exon 14 Skipping alteration: approved as a single agent for first- or subsequent-line therapy. However, per NCCN, targeted therapy for the oncogenic driver should take precedence over an immune checkpoint inhibitor.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Biomarker Criteria:\n",
      "Sample must match all of the following:Sample must match one or more of the following:PD-L1 High Expression, PD-L1 Low ExpressionSample must match one or more of the following:BRAF V600E, RET Fusion, ROS1 Fusion, MET Exon 14 Skipping\n",
      "\n",
      "Clinical Setting(s):  Metastatic (FDA, NCCN)\n",
      "\n",
      "\n",
      "Note:  For PD-L1 expressing tumors (Tumor Proportion Score >=1%, clone 22C3) with a ROS1, RET, BRAF V600E, or MET Exon 14 Skipping alteration: approved as a single agent for first- or subsequent-line therapy. However, per NCCN, targeted therapy for the oncogenic driver should take precedence over an immune checkpoint inhibitor.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Biomarker Criteria:\n",
      "Sample must match one or more of the following:PD-L1 High Expression, PD-L1 Low Expression\n",
      "\n",
      "\n",
      "\n",
      "Clinical Setting(s):  Second Line of Therapy (NICE, SMC)\n",
      "\n",
      "\n",
      "Note:  Pembrolizumab is indicated as subsequent therapy for patients with NSCLC expressing CD274 (programmed death ligand 1 (PD-L1)), and whose disease has progressed on or after platinum-containing chemotherapy. An improved overall response rate was observed in CD274 (PD-L1) positive tumors.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Biomarker Criteria:\n",
      "Sample must match one or more of the following:PD-L1 High Expression, PD-L1 Low Expression\n",
      "\n",
      "Clinical Setting(s):  Second Line of Therapy (NICE, SMC)\n",
      "\n",
      "\n",
      "Note:  Pembrolizumab is indicated as subsequent therapy for patients with NSCLC expressing CD274 (programmed death ligand 1 (PD-L1)), and whose disease has progressed on or after platinum-containing chemotherapy. An improved overall response rate was observed in CD274 (PD-L1) positive tumors.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "Biomarker Criteria:\n",
      "Sample must match all of the following:PD-L1 Low Expression\n",
      " \n",
      "\n",
      "Clinical Setting(s):  Metastatic (FDA, NCCN, ASCO)\n",
      "\n",
      "\n",
      "Note:  For low expression of PD-L1 (Tumor Proportion Score >= 1% and <50%, clone 22C3) in the absence of EGFR & ALK (FDA/NCCN) and ROS1, RET, BRAF V600E, and MET Exon 14 Skipping (NCCN) mutations: recommended as a single agent for first-line therapy (for patients with contraindications to combination chemotherapy, per NCCN), or as subsequent line with disease progression during or following appropriate systemic chemotherapy.\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "for entry in entries[-1:]:\n",
    "    cancer = entry.find(class_='about-drug-therapy-header').text\n",
    "    sensitivity = entry.find(class_='about-drug-therapy-sensitivity-row').text\n",
    "    biomarker = entry.find(class_='small-12 columns biomarker-criteria').text\n",
    "    clinical = entry.find(class_='small-12 columns response-setting-note').text\n",
    "    print(cancer, sensitivity, biomarker, clinical)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "beacb2a5",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<div class=\"about-drug-therapy-row\">\n",
       "<p class=\"about-drug-therapy-header\" onclick=\"toggleDisplay('about-drug-therapy-toggle-1');\">\n",
       "                    Breast Carcinoma\n",
       "                    <span class=\"indicator\" id=\"indicator-about-drug-therapy-toggle-1\">+</span>\n",
       "</p>\n",
       "<div class=\"about-drug-therapy-content\" id=\"target-about-drug-therapy-toggle-1\" style=\"display: none\">\n",
       "<div class=\"about-drug-therapy-sensitivity-row\">\n",
       "<p class=\"about-drug-therapy-sensitivity-header\" onclick=\"toggleDisplay('about-drug-therapy-sensitivity-toggle-1');\">\n",
       "<b>Disease is predicted to be sensitive to pembrolizumab:</b>\n",
       "<span class=\"indicator\" id=\"indicator-about-drug-therapy-sensitivity-toggle-1\">-</span>\n",
       "</p>\n",
       "<div class=\"about-drug-therapy-sensitivity-content row\" id=\"target-about-drug-therapy-sensitivity-toggle-1\">\n",
       "<div class=\"row table-row targeted-therapy-table-small-screen-container\">\n",
       "<div class=\"small-12 columns biomarker-criteria\">\n",
       "<strong>Biomarker Criteria:</strong>\n",
       "<div class=\"therapy_criteria_header\">Sample must match <strong>all</strong> of the following:<div style=\"padding-left: 1em;\"><div class=\"therapy_criteria_header\">Sample must match <strong>one or more</strong> of the following:<div class=\"therapy_criteria\"><a class=\"underline-hover\" href=\"/content/alteration/pd-l1-expression\">PD-L1 Expression</a></div></div><div class=\"therapy_criteria_header\">Sample must match <strong>one or more</strong> of the following:<div class=\"therapy_criteria\"><a class=\"underline-hover\" href=\"#\" onclick=\"alterationModal.showModalFor(114);\">Triple-Negative Breast Cancer Alterations</a></div></div></div></div>\n",
       "</div>\n",
       "<div class=\"small-12 columns response-setting-note\">\n",
       "<div class=\"row\">\n",
       "<div class=\"small-12 columns\"><i><u>Clinical Setting(s):</u></i>  Metastatic (<a class=\"underline-hover\" href=\"/content/glossary/#fda\">FDA</a>, <a class=\"underline-hover\" href=\"/content/glossary/#nccn\">NCCN</a>)</div>\n",
       "</div>\n",
       "<div class=\"row\">\n",
       "<div class=\"small-12 columns\"><i><u>Note:</u></i>  Indicated in combination with chemotherapy for patients with locally recurrent, unresectable, or metastatic TNBC whose tumors express PD-L1 [Combined Positive Score (CPS) &gt;= 10].</div>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "<div class=\"targeted-therapy-table-large-screen-container\">\n",
       "<table class=\"targeted-therapy-table-large-screen\">\n",
       "<tr>\n",
       "<td class=\"right-column\" rowspan=\"2\">\n",
       "<strong>Biomarker Criteria:</strong>\n",
       "<div class=\"therapy_criteria_header\">Sample must match <strong>all</strong> of the following:<div style=\"padding-left: 1em;\"><div class=\"therapy_criteria_header\">Sample must match <strong>one or more</strong> of the following:<div class=\"therapy_criteria\"><a class=\"underline-hover\" href=\"/content/alteration/pd-l1-expression\">PD-L1 Expression</a></div></div><div class=\"therapy_criteria_header\">Sample must match <strong>one or more</strong> of the following:<div class=\"therapy_criteria\"><a class=\"underline-hover\" href=\"#\" onclick=\"alterationModal.showModalFor(114);\">Triple-Negative Breast Cancer Alterations</a></div></div></div></div>\n",
       "</td>\n",
       "<td class=\"left-column\"><i><u>Clinical Setting(s):</u></i>  Metastatic (<a class=\"underline-hover\" href=\"/content/glossary/#fda\">FDA</a>, <a class=\"underline-hover\" href=\"/content/glossary/#nccn\">NCCN</a>)</td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td class=\"left-column last\"><i><u>Note:</u></i>  Indicated in combination with chemotherapy for patients with locally recurrent, unresectable, or metastatic TNBC whose tumors express PD-L1 [Combined Positive Score (CPS) &gt;= 10].</td>\n",
       "</tr>\n",
       "</table>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "</div>"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "entries[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "81119fa6",
   "metadata": {},
   "outputs": [],
   "source": [
    "'''\n",
    "- confirm how to pull the drugs in the database (e.g. all drugs with FDA approval)\n",
    "- https://www.mycancergenome.org/content/drugs/imatinib/ figure out how to parse examples such as this one  thhttps://www.mycancergenome.org/content/drugs/imatinib/at have both sensitive and resistant in the same page + drug + cancer type-\n",
    "'''"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
